Sequential Exposure of Bortezomib and Vorinostat is Synergistic in Multiple Myeloma Cells

Purpose To examine the combination of bortezomib and vorinostat in multiple myeloma cells (U266) and xenografts, and to assess the nature of their potential interactions with semi-mechanistic pharmacodynamic models and biomarkers.